Zhejiang Medicine Co., Ltd. (SHA:600216)

Market Cap	13.85B +5.7%
Revenue (ttm)	8.82B -6.0%
Net Income	751.31M -48.5%
EPS	0.78 -49.3%
Shares Out	947.91M
PE Ratio	18.70
Forward PE	12.37
Dividend	0.28 (1.92%)
Ex-Dividend Date	Jul 21, 2025

Volume	14,168,382
Average Volume	27,161,793
Open	14.56
Previous Close	14.56
Day's Range	14.51 - 14.74
52-Week Range	13.29 - 18.58
Beta	0.58
RSI	38.30
Earnings Date	Apr 11, 2026

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and medical products in China and internationally. The company offers synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin. It also provides fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, injectable vancomycin hydrochloride injections, and injectable teicoplanin produc...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 5,815
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600216

Financial Performance

In 2025, Zhejiang Medicine's revenue was 8.88 billion, a decrease of -5.28% compared to the previous year's 9.38 billion. Earnings were 873.38 million, a decrease of -24.74%.